QLGN - הכנסה תפעולית לפני ניכוי פחת Qualigen Therapeutics, Inc.

By combining diagnostic test sales with the development of oncology drugs, Qualigen Therapeutics (QLGN) is stabilizing its cash flow. The operating profit (EBIT) trend confirms this dynamic, where shows the value of this parameter. The strategy relies on the AS1411 platform, which locks clinics into its protocols, although the focus on anti-tumor developments maintains high binary risks for capital.

This indicator measures real cash flow from operating activities, excluding non-cash charges and depreciation to assess the actual solvency of the business. By analyzing the operating financial result, an investor can see the efficiency of Qualigen Therapeutics (QLGN) transitioning toward organic growth and targeted licensing agreements, which confirms the viability of the company's core without relying on aggressive acquisitions.